Cargando…

Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study

AIMS: To evaluate the impact of SARS-CoV-2 vaccine on IBD activity. METHODS: Adult IBD patients from five large IBD centers in China were enrolled and followed up for 6 months. Patients were divided into vaccinated and unvaccinated groups according to vaccination status. Demographic and clinical dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mingjun, Huang, Qing, Shi, Chenchen, Feng, Yun, Duan, Tianjiao, Lin, Tianyu, Zhu, Yuanmin, Liu, Guisheng, Li, Hongxia, Liu, Yulan, Jiang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910246/
https://www.ncbi.nlm.nih.gov/pubmed/36757427
http://dx.doi.org/10.1007/s00384-023-04315-x
_version_ 1784884745280159744
author Zhang, Mingjun
Huang, Qing
Shi, Chenchen
Feng, Yun
Duan, Tianjiao
Lin, Tianyu
Zhu, Yuanmin
Liu, Guisheng
Li, Hongxia
Liu, Yulan
Jiang, Bo
author_facet Zhang, Mingjun
Huang, Qing
Shi, Chenchen
Feng, Yun
Duan, Tianjiao
Lin, Tianyu
Zhu, Yuanmin
Liu, Guisheng
Li, Hongxia
Liu, Yulan
Jiang, Bo
author_sort Zhang, Mingjun
collection PubMed
description AIMS: To evaluate the impact of SARS-CoV-2 vaccine on IBD activity. METHODS: Adult IBD patients from five large IBD centers in China were enrolled and followed up for 6 months. Patients were divided into vaccinated and unvaccinated groups according to vaccination status. Demographic and clinical data were collected. RESULTS: A total of 280 individuals (213 UC and 67 CD patients) were enrolled in the study. The unvaccinated and vaccinated groups of UC patients were comparable for basic characteristics, including age (t = − 0.8, p = 0.425), sex (χ(2) = 0.980, p = 0.322), course of disease (z = − 0.513, p = 0.608), surgical conditions (χ(2) = 1.042, p = 0.838), disease extent (χ(2) = 4.853, p = 0.088), or baseline drug therapy (χ(2) = 7.784, p = 0.064). In the subgroup of UC patients, there was no association between vaccination and disease activities, according to the medium disease activity scores for two groups: unvaccinated patients having scores (IQR) 1(2.75), 1(2), 1(2), and 1(2) at baseline, 1, 3, and 6 months, respectively, whereas vaccinated patients having scores (IQR) 1(2), 1(2), 1(2), and 1(2). Similar conclusions were also derived in the subgroup of CD patients. There were also no statistically significant differences in age (t = − 1.48, p = 0.144), sex (χ(2) = 0.003, p = 0.957), course of disease (z = − 0.074, p = 0.941), surgical conditions (χ(2) = 0.613, p = 0.594), localization (χ(2) = 6.261, p = 0.199), or baseline drug therapy (χ(2) = 5.881, p = 0.114) between 2 groups of CD patients. The medium disease activity scores (IQR) of the unvaccinated group at baseline, 1, 3, and 6 months were 1(4), 1(3), 1(3), and 1(3), respectively, whereas those of vaccinated group were 2.5(3.75), 2.5(3.75), 3(2), and 2(2), respectively. Overall, very few participants in this study described worsening IBD disease activity requiring a change or addition of medication. CONCLUSIONS: SARS-CoV-2 vaccine has no adverse effect on disease activity in IBD population. IBD patients should be recommended to receive SARS-CoV-2 vaccine in time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00384-023-04315-x.
format Online
Article
Text
id pubmed-9910246
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99102462023-02-10 Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study Zhang, Mingjun Huang, Qing Shi, Chenchen Feng, Yun Duan, Tianjiao Lin, Tianyu Zhu, Yuanmin Liu, Guisheng Li, Hongxia Liu, Yulan Jiang, Bo Int J Colorectal Dis Research AIMS: To evaluate the impact of SARS-CoV-2 vaccine on IBD activity. METHODS: Adult IBD patients from five large IBD centers in China were enrolled and followed up for 6 months. Patients were divided into vaccinated and unvaccinated groups according to vaccination status. Demographic and clinical data were collected. RESULTS: A total of 280 individuals (213 UC and 67 CD patients) were enrolled in the study. The unvaccinated and vaccinated groups of UC patients were comparable for basic characteristics, including age (t = − 0.8, p = 0.425), sex (χ(2) = 0.980, p = 0.322), course of disease (z = − 0.513, p = 0.608), surgical conditions (χ(2) = 1.042, p = 0.838), disease extent (χ(2) = 4.853, p = 0.088), or baseline drug therapy (χ(2) = 7.784, p = 0.064). In the subgroup of UC patients, there was no association between vaccination and disease activities, according to the medium disease activity scores for two groups: unvaccinated patients having scores (IQR) 1(2.75), 1(2), 1(2), and 1(2) at baseline, 1, 3, and 6 months, respectively, whereas vaccinated patients having scores (IQR) 1(2), 1(2), 1(2), and 1(2). Similar conclusions were also derived in the subgroup of CD patients. There were also no statistically significant differences in age (t = − 1.48, p = 0.144), sex (χ(2) = 0.003, p = 0.957), course of disease (z = − 0.074, p = 0.941), surgical conditions (χ(2) = 0.613, p = 0.594), localization (χ(2) = 6.261, p = 0.199), or baseline drug therapy (χ(2) = 5.881, p = 0.114) between 2 groups of CD patients. The medium disease activity scores (IQR) of the unvaccinated group at baseline, 1, 3, and 6 months were 1(4), 1(3), 1(3), and 1(3), respectively, whereas those of vaccinated group were 2.5(3.75), 2.5(3.75), 3(2), and 2(2), respectively. Overall, very few participants in this study described worsening IBD disease activity requiring a change or addition of medication. CONCLUSIONS: SARS-CoV-2 vaccine has no adverse effect on disease activity in IBD population. IBD patients should be recommended to receive SARS-CoV-2 vaccine in time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00384-023-04315-x. Springer Berlin Heidelberg 2023-02-09 2023 /pmc/articles/PMC9910246/ /pubmed/36757427 http://dx.doi.org/10.1007/s00384-023-04315-x Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research
Zhang, Mingjun
Huang, Qing
Shi, Chenchen
Feng, Yun
Duan, Tianjiao
Lin, Tianyu
Zhu, Yuanmin
Liu, Guisheng
Li, Hongxia
Liu, Yulan
Jiang, Bo
Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study
title Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study
title_full Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study
title_fullStr Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study
title_full_unstemmed Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study
title_short Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study
title_sort effects of sars-cov-2 vaccine (vero cells) on disease activity in patients with inflammatory bowel disease in china: a multicenter study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910246/
https://www.ncbi.nlm.nih.gov/pubmed/36757427
http://dx.doi.org/10.1007/s00384-023-04315-x
work_keys_str_mv AT zhangmingjun effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT huangqing effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT shichenchen effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT fengyun effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT duantianjiao effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT lintianyu effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT zhuyuanmin effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT liuguisheng effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT lihongxia effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT liuyulan effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy
AT jiangbo effectsofsarscov2vaccineverocellsondiseaseactivityinpatientswithinflammatoryboweldiseaseinchinaamulticenterstudy